Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.6000
-0.0585 (-8.88%)
At close: May 15, 2026, 4:00 PM EDT
0.5878
-0.0122 (-2.03%)
Pre-market: May 18, 2026, 4:52 AM EDT
Galmed Pharmaceuticals Employees
As of December 31, 2025, Galmed Pharmaceuticals had 6 total employees, including 3 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,718,167
Market Cap
3.95M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | 0 | - | 3 | 3 |
| Dec 31, 2024 | 6 | -2 | -25.00% | 3 | 3 |
| Dec 31, 2023 | 8 | -2 | -20.00% | 3 | 5 |
| Dec 31, 2022 | 10 | -14 | -58.33% | 4 | 6 |
| Dec 31, 2021 | 24 | 0 | - | 19 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BiomX | 20 |
| GeoVax Labs | 19 |
| VivoSim Labs | 14 |
| Soligenix | 14 |
| Revelation Biosciences | 9 |
| Akari Therapeutics, | 6 |
| Alzamend Neuro | 6 |
| CNS Pharmaceuticals | 5 |
GLMD News
- 3 days ago - Galmed reports results from first-in-man PK study of Aramchol Meglumine - TheFly
- 3 days ago - Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg - PRNewsWire
- 11 days ago - Galmed partnering with Tissue Dynamics to develop cardiac fibrosis platform - TheFly
- 11 days ago - Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics - PRNewsWire
- 4 weeks ago - Galmed announces research agreement with Ramot at Tel Aviv University - TheFly
- 4 weeks ago - Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers - PRNewsWire
- 5 weeks ago - Why Is Galmed Pharmaceuticals Stock (GLMD) Up Today? - TipRanks
- 5 weeks ago - Galmed announces development of brain penetrating formulation of Aramchol - TheFly